Advanced search×

Effects of epilepsy and antiepileptic drugs on nitric oxide, lipid peroxidation and xanthine oxidase system in children with idiopathic epilepsy

Ebru Arhan, Ayse Serdaroglu, Bahadır Ozturk, H Serdar Ozturk, Aysima Ozcelik, Nese Kurt, Ebru Kutsal, and Neriman Sevinc

Seizure 20(2):5 (2011) PMID 21112224

The aim of this study is to investigate the effects of epilepsy, valproic acid and oxcarbazepine on nitric oxide levels, lipid peroxidation and xanthine oxidase levels in newly diagnosed epileptic children and healthy controls. A total of 49 patients with newly diagnosed idiopathic epilepsy and 15 healthy children were enrolled in this study. Of these 49 patients, 16 children were treated with valproate and 16 treated with oxcarbazepine. Nitric oxide, malondialdehyde and xanthine oxidase levels prior to antiepileptic drug therapy were measured in the serum. Blood samples were drawn before antiepileptic drug therapy and after 3 and 6 months of the antiepileptic drug treatment. Nitric oxide levels were statistically higher in the newly diagnosed epileptic patients. In oxcarbazepine group, the nitric oxide and malondialdehyde levels were found to be decreased. No statistically significant differences were noted in nitric oxide, malondialdehyde and xanthine oxidase levels in valproic acid treated group. Oxcarbazepine which is a frequently used new antiepileptic drug in childhood epilepsy may modify nitric oxide levels and lipid peroxidation. These results suggest that decreased lipid peroxidation would play a role in the mechanism of antiepileptic effects by oxcarbazepine treatment.

Copyright © 2011 Elsevier Ltd. All rights reserved.

DOI: 10.1016/j.seizure.2010.11.003
Version: za2963e q8za5 q8zb5 q8zc9 q8zd6 q8ze1 q8zf2 q8zgf
Buy PDF

Similar articles you may find interesting…

  1. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies.
    Prithviraj Bose, Gary L Simmons, and Steven Grant

    Expert Opin Investig Drugs (2013) PMID 23647051

    Cyclin-dependent kinases (CDKs) regulate cell cycle progression. Certain CDKs (e.g., CDK7, CDK9) also control cellular transcription. Consequently, CDKs represent attractive targets for anticancer drug development, as their aberrant expression is common in diverse malignancies, and CDK inhibition ca...
    Buy PDF
  2. Phase I/II RAF kinase inhibitors in cancer therapy.
    Samra Turajlic, Zohra Ali, and James Larkin

    Expert Opin Investig Drugs (2013) PMID 23642225

    Aberrant activation of RAF signalling is a frequent finding in human cancers. BRAF is the only RAF family member that is commonly mutated, whilst CRAF and ARAF play important roles in the signal transduction from mutant RAS. BRAF-specific inhibitors have been more effective in the treatment of BRAF-...
    Buy PDF
  3. UDP-glucuronosyltransferase 2B15 (UGT2B15) is the Major Enzyme Responsible for Sipoglitazar Glucuronidation in Humans: Retrospective Identif...
    Mitsuhiro Nishihara, Yuto Hiura, and Satoru Asahi

    Drug Metab Pharmacokinet (2013) PMID 23648677

    These results show that sipoglitazar is a good example to elucidate the relationship between phenotype and genotype for UGT2B15 from in vitro analysis....
    PDF not found